SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):147P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Castellucci, P.
Right arrow Articles by Fanti, S.
PubMed
Right arrow Articles by Castellucci, P.
Right arrow Articles by Fanti, S.

Oncology-Clinical Diagnosis: Hematologic Tumors

Clinical Diagnosis: Hematologic Tumors Posters

FDG-PET in the assessment of patients with non-Hodgkin's lymphoma treated by ibritumomab tiuxetan

Paolo Castellucci1, PierLuigi Zinzani2, GianCarlo Montini1, Monica Tani2, Ivan Santi1, Vittorio Stefoni2, Domenico Rubello3, Valentina Ambrosini1, Roberto Franchi1 and Stefano Fanti1

1 Nuclear Medicine; 2 Haematology, Policlinico S. Orsola, Bologna, Italy; 3 Ospedale S. Maria della Misericordia, Rovigo, Italy

584

Objectives: Aim of the study was to investigate the value of FDG-PET scans before and after treatment in non-Hodgkin's lymphoma (NHL) patients treated by radioimmunotherapy (RIT) with ibritumomab tiuxetan (IT).

Methods: NHL patients who underwent a IT treatment for relapse were enrolled in the study (38 cases) and scheduled for FDG PET scans before and three months after RIT. All patients had a final assessment using clinical data at 6 months as gold standard. FDG PET findings were reported as positive in presence of pathologic tracer uptake, and scans categorized in relation to the extent of disease.

Results: PET documented relapse in all 38 cases; the extent of disease at relapse was limited to one side of the diaphragm in 20 cases (7 above and 13 below), involving nodal sites at both sides of diaphragm in 11 cases and involving also extra-nodal sites in 7 cases. At final assessment (follow-up at 6 months), treatment with IT resulted in complete remission in 21 patients (55% of cases), partial remission in 13 patients (34%) and progressive disease in 4 patients (11%). When comparing the PET extent of the disease at relapse and the response, we observed a higher rate of complete response in patients with limited disease (15/20) as compared to those with extra-nodal extent (1/7). Finally in all cases FDG PET at three months was consistent with clinical findings at follow-up.

Conclusions: Our results confirm that FDG PET is a valid tool for NHL evaluation, for both assessing the relapse and documenting the response to RIT. We also found a correlation between the extent of relapse and the likelyhood of complete response to IT treatment.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Castellucci, P.
Right arrow Articles by Fanti, S.
PubMed
Right arrow Articles by Castellucci, P.
Right arrow Articles by Fanti, S.